Kornimate/medical-research-clean huggingface dataset:
study of accuracy of new diagnostic technology to guide rapid antibiotic treatment for serious infections

Conditions: INFECTIONS; Skin and Subcutaneous Tissue Bacterial Infections; Healthcare-associated Infection; Infection Due to Resistant Bacteria

Summary: this research will test a new ultra-rapid technology (called id/ast accelerate system) that uses a digital microscope to identify bacteria based on their growth patterns. this method does not have to wait for bacteria to grow in a lab. the new method can identify the type of bacteria within 2 hours of receiving a specimen. the new method also shows the effect of selected antibiotics on the bacteria including multidrug resistant bacteria so that doctors know within 6 hours from specimen collection which antibiotic kills the bacteria. to check the accuracy, speed and impact of the new method on antibiotic prescribing, investigators are proposing a study with two parts; the first part will test the accuracy and speed of the results obtained by the new method. the second part will test if having the results from the new method early would change the antibiotics prescribed to a patient in a simulation experiment. an independent infectious disease physician will be shown the results from the new method and asked if the results were accurate, would it change the antibiotic treatment for the patient.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * remnant sample from available from microbiology culture (respiratory, blood or tissue/skin) ordered as part of usual clinical care. exclusion criteria: * insufficient sample volume available after sufficient aliquot removed for usual care.

Keywords: wounded warriors battlefield infection esbl mrsa kpc
effects of coenzyme q10 in progressive supranuclear palsy (psp)

Conditions: Progressive Supranuclear Palsy

Summary: the clinical syndrome of psp responds poorly to all available forms of therapy used in parkinson's disease (pd). currently, no effective treatment exists. coenzyme q10 in high doses has been shown to be a beneficial therapy in pd and might possibly be a beneficial therapy for psp. this study will compare the efficacy, safety and tolerability of coenzyme q10 versus placebo in patients with atypical parkinsonian syndrome, progressive supranuclear palsy (psp).

the study is designed as a multicenter randomized, placebo-controlled, double blind trial. up to 60 patients with psp will be enrolled at several centers in the united states

Eligibility criteria:
inclusion criteria: * patients fulfilling the diagnostic criteria of psp/diagnosed within the past 5 years * either vertical supranuclear palsy or both slowing of vertical saccades * prominent postural instability with falls in the first year of disease onset * no evidence of other diseases that could explain the foregoing features exclusion criteria: * current or previous therapeutic use of coq10 * parkinsonism due to drugs * history of pallidotomy, thalamotomy, active deep brain stimulator or fetal tissue transplant * history of active epilepsy, stroke, structural brain disease * use of methylphenidate hydrochloride, cinnarizine, reserpine, amphetamines, or monoamine oxidase-a inhibitors within 3 months before the baseline visit. * active cancer or cancer undergoing treatment * participation in other drug studies or the use of other investigational drugs within 30 days before screening. * known hypersensitivity to coenzyme q10. * pregnant, planning a pregnancy or nursing woman

Keywords: progressive supranuclear palsy coq10 coenzyme q10
social egg freezing: will health professionals offer it ?

Conditions: Infertility,Female

Summary: in 2021, the revision of bioethics laws opened the door to elective egg freezing. this gives women, between their 29th and 37th birthdays, the opportunity to freeze their eggs in order to combat age decline fertility. however, communication about this new possibility has remained limited both toward women and their health professional.

thus, the hypothesize of this study is that these professionals, namely physicians, gynecologists and midwives, are insufficiently aware of age-related fertility decline and unaware of the possibility of elective egg freezing. this multicenter observational cross-sectional study whose objective will be: * to assess the knowledge of these professionals in terms of age-related fertility decline. * to measure their propensity to spontaneously broach the subject with their childless patients. * to assess their knowledge and support for elective egg freezing. this study will be done using an online questionnaire that will be distributed in electronic format to all the health professionals concerned in the participating areas. this study will provide valuable knowledge on the perception of elective egg freezing by health professionals, determine their training needs and motivate new information campaigns on this subject.

Eligibility criteria:
inclusion criteria: * be a general practitioner, gynecologist or midwife in practice for at least one year * follow patients between 29 and 37 years old (for their contraception for example) exclusion criteria: * have been practising for less than a year * have no patients aged between 29 and 37

Keywords: elective egg freezing attitude of health professionals health knowledge aging female infertility
study evaluating the safety and tolerability of ilv-094 in subjects with psoriasis

Conditions: Psoriasis

Summary: the purpose of this study is to assess safety, and tolerability of multiple doses of ilv-094 administered to subjects with psoriasis


Eligibility criteria:
inclusion criteria: * men and women of nonchildbearing potential 18 years or older. * physician area and severity index (pasi) greater than 11. * physician global assessment (pga) greater than 3. exclusion criteria: * use of any investigational small -molecule drug within 30 days before the first dose of test article administration, and use of any investigational biologic agents within 5 half lives before study day 1, or 90 days for investigational biologics that may have a long clinical duration of effect. * live vaccines within 3 months before test article administration or during the study. * use of any biologic therapy within approximately 5 half-lives before test article administration. approximate half-lives of biologic therapies approved for psoriasis are as follows: enbrel, 5 days; humira, 14 days; remicade, 9 days; amevive, 12 days; raptiva, 6 days. it is recommended that amevive be discontinued for at least 90 days because of its long clinical duration of action. * psoralen plus ultraviolet a radiation (puva) therapy within 4 weeks before study day 1. * ultraviolet b (uvb) therapy within 2 weeks before study day 1. * receipt of systemic psoriasis therapy (eg, oral retinoids, methotrexate, hydroxyurea, cyclosporine, or azathioprine) or systemic corticosteroids within 4 weeks before study day 1. * topical steroids, topical vitamin a or d analog preparations, or anthralin within 2 weeks before study day 1. (exception: topical therapies, including steroids at no higher than mild strength \[class 6 or 7 topical corticosteroids\], are permitted on the scalp, axillae, face, and groin, but the dose of the medication must be kept stable throughout the trial.)
evaluation of the safety and performance of a bioresorbable nasal dressing containing mometasone furoate

Conditions: Rhinosinusitis Chronic; Wound Healing; Sinus Surgery; Mometasone Furoate

Summary: the objective of this study is to investigate the safety and performance of ocean® as an adjunct in wound healing after nasal/sinus surgery by using ocean® in patients undergoing nasal/sinus surgery.


Eligibility criteria:
inclusion criteria: 1. patient is 18 years or older 2. patient is scheduled to undergo bilateral endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps (crswnp) or chronic rhinosinusitis without nasal polyps (crssnp) 3. patient is willing and able to comply with all study elements as indicated by their written informed consent 4. patients with a pre-operative lund-mackay score of ≥ 6. exclusion criteria: 1. patient is pregnant or nursing 2. patients with a history of chronic epistaxis or experienced a significant epistaxis event (defined as epistaxis requiring medical intervention) in the past 3 months 3. patients with a platelet disorder 4. patients with a known or suspected allergy to device components 5. patients with known hemophilia 6. patients with insulin dependent diabetics 7. patients with an oral steroid dependent condition 8. patients with glaucoma, ocular hypertension, posterior subcapsular cataracts 9. patients with a (previous) diagnosis of samter's triad (aspirin-exacerbated respiratory disease (aerd)) 10. patients that require nasal ointments or creams at time of device placement 11. patients with a neurological, medical, psychiatric condition, or social circumstance that would potentially increase risk, interfere with study participation, or confound interpretation of study data 12. patients with plans to (or otherwise anticipate the need to) undergo an ear, nose, throat (ent) procedure within the 90 day study follow up 13. patients participating in another clinical research study (within 30 days prior to screening up till 90 days post-operative). 14. patients that used any form of corticosteroid or immunologics within 2 weeks prior to sinus surgery or during follow-up to day 30.
study of nutrition and exercise in adults hospitalized for treatment of acute lymphoblastic leukemia (all)

Conditions: Philadelphia Chromosome Negative; B Cell Acute Lymphoblastic Leukemia (B-ALL); B-ALL

Summary: this clinical trial aims to assess the effect of nutrition and exercise on muscle and adiposity in adults with philadelphia chromosome (ph) negative b-all undergoing inpatient induction therapy. participants will take part in 2 different interventions: * nutrition intervention * physical exercise intervention all subjects will be provided with a wearable electronic activity monitor (fitbit®) to assist in recording activity levels in minutes of activity.


Eligibility criteria:
inclusion criteria: * new diagnosis of philadelphia chromosome negative b-all * receiving intensive pediatric-inspired induction chemotherapy exclusion criteria: * bmi ≤18.5 kg/m2 at time of diagnosis * unable to comply with both the recommended diet and exercise regimen as deemed by the research or treatment team * pregnant
trial to assess the efficacy of malaria vaccine pfcs 102

Conditions: Plasmodium Falciparum Malaria

Summary: phase i/iia double-blind randomized (adjuvant)-controlled trial. 16 volunteers are randomized to receive two doses of either 30 µg of pfcs102 formulated in montanide isa 720 (verum) or isa 720 alone (control), 60 days apart. two weeks after the 2nd immunization, 14 volunteers are challenged with bites of 5 infected mosquitoes using the nf54 strain of p. falciparum. the main outcome will be the length of time between artificial challenge and development of blood stage parasitaemia detected by microscopy performed twice a day.


Eligibility criteria:
inclusion criteria: * resident in or near lausanne; * age \>18 and \<45 years; * written informed consent; * \>10/12 correct responses to the questionnaire of understanding. exclusion criteria: * history of malaria; possible exposure to malaria within the previous 6 months; * positive serology for pfcs102by elisa; * history of severe reactions or allergy to mosquito bites, artemether/lumefantrine (riamet®) or vaccines; * pregnant or lactating female; * any confirmed or suspected immunodeficient condition; * seropostivity for hiv; * chronic or active neurological, gastrointestinal, cardio-vascular or respiratory disease; * hemoglobinopathies; * history of \>2 hospitalisations for invasive bacterial infections; * requirement of any chronic medication; * suspected or known current alcohol or illegal drug abuse (excluding cannabis); * any other significant finding which, in the opinion of the investigator, would significantly increase the risk of having an adverse outcome from participating in this protocol or of dropping out of the study; * a body mass index \ 32 kg/m2; * evidence of past or present psychiatric condition; * seropositivity for hiv, hepatitis c or b (other than hbs ab); * 10-year risk of coronary heart disease \<10%; * any clinically significant deviation from the normal range in biochemistry or haematology blood tests or in urine analysis.

Keywords: plasmodium falciparum malaria
prospective evaluation of stereotactic body radiotherapy for metastatic prostate cancer

Conditions: Metastatic Prostate Cancer

Summary: the investigators aim to test the safety and feasibility of prostate gland stereotactic body radiotherapy (sbrt) plus best systemic therapy in newly diagnosed metastatic prostate cancer.

the investigators and other investigators have previously documented the safety and efficacy of definitive intent stereotactic body radiotherapy (sbrt) in the treatment of localized prostate cancer. in the metastatic setting for multiple malignancies, improved survival rates and disease outcomes have been shown with definitive treatment of the primary disease site. this concept of "cytoreductive" surgery or decreasing the primary tumor burden is now considered the standard of care for metastatic colon, ovarian, renal cell, and some breast carcinomas (plus post-surgery irradiation). with new guidelines and declining rates of psa screening, the incidence of newly diagnosed metastatic prostate cancer is expected to increase. a recent population-based study has concluded significant improvements in the definitive treatment of the local prostate cancer in the stage iv setting with either radical prostatectomy or conventional prostate radiation treatments/brachytherapy. to our knowledge, one prospective phase ii trial is currently accruing patients to best systemic therapy or best systemic therapy (bst) plus definitive treatment with either radical prostatectomy or conventionally fractionated radiation therapy the investigators hypothesize that the addition of primary disease sbrt to best systemic therapy for newly diagnosed metastatic prostate cancer would be associated with an acceptable safety profile, quality of life, disease progression, and overall survival. the addition of sbrt to best systemic therapy is also expected to be better-received for stage iv patients (with relatively limited prognosis), vs. fully fractionated radiation therapy, brachytherapy, or radical prostatectomy. the above endpoints would initially be tested in a prospective phase ii multi-institutional trial and in comparison with historical controls.

Eligibility criteria:
inclusion criteria: * histologically-confirmed, adenocarcinoma of the prostate * clinical stage t1b - t4, nx-0-1, m1 * any gleason score * psa\<1000 * ecog performance status 0-2 * no prior prostate radiation or other definitive therapy exclusion criteria: * prior prostatectomy or cryotherapy of the prostate * prior radiotherapy to the prostate or lower pelvis * implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion * chemotherapy for a malignancy in the last 5 years * history of an invasive malignancy (other than this prostate cancer, or basal or squamous skin cancers) in the last 5 years

Keywords: metastatic prostate cancer
magnetic therapy and cervical stabilization exercises in cervical spondylosis

Conditions: Cervical Spondylosis

Summary: the purposes of this study are to investigate adding low frequency high intensity magnetic therapy to cervical stabilization exercises on pain intensity, function, rom, cervical endurance, and cervical proprioception errors in patients with cervical spondylosis.

cervical spondylosis is a chronic degenerative process of the cervical spine. pain in the neck and/or arms, neck stiffness, and headaches are the usual symptoms of cervical spondylosis . low frequency high intensity magnetic therapy causes short term immediate effect in the relieve pain and improve function in patients with cervical spondylosis . cervical stabilization causes decrease in neck pain and neck disability as well as a significant increase in cervical muscle endurance and cervical range of motion after the intervention. it also demonstrates a more ideal upper body posture and improved cervical proprioception. in the present study, therefore, we aimed to investigate adding low frequency high intensity magnetic therapy to cse on management of cervical spondylosis. this study will be a benefit in the physical therapy field and may guide rehabilitation programs of physical therapy towards better results through decreasing time needed to perform activity of daily living, decreasing dependency and making patient an active member in society.

Eligibility criteria:
inclusion criteria: * eighty cervical spondylosis patients from both sexes will be participated in this study. * the patients' ages will be ranged from 30-45 years to prevent aging process. * x-ray evidence of cervical spondylosis (osteophyte formation, intervertebral disc height narrowing and vertebral end-plate sclerosis) . * the presence of chronic neck pain (more than 3 months). * limited mobility in the cervical spine. exclusion criteria: * the following patients will be excluded from the study patients with: * history of cervical injury of trauma. * cervical myelopathy. * inflammatory arthritis involving cervical spine. * tumor or infection involving cervical spine. * vertebrobasilar artery insufficiency. * neurologic disease (e.g. multiple sclerosis, parkinson's disease, syringomyelia). * congenital anomalies involving cervical spine. * diabetes mellitus. * vestibular system impairments.

Keywords: cervical spondylosis - magnetic therapy
cst1 predictive model of oral glucocorticoid therapy sensitivity for chronic rhinosinusitis with polyps

Conditions: Chronic Rhinosinusitis With Nasal Polyps; Glucocorticoids

Summary: topical and systemic steroids constitute the first choice in medical treatment for nasal polyps. glucocorticoids sensitivity is significantly correlated with cst1 level in nasal secretions. the goal of this single-arm clinical trial based on a multicenter platform is to test cst1 in patients with chronic rhinosinusitis and nasal polyps before and after oral glucocorticoid therapy. endoscopic polyp score, total nasal symptom score(tnss), snot-22 score and other biomarkers are also evaluated before and after the treatment. researchers will develop a cst1 predictive model of oral glucocorticoid therapy for chronic rhinosinusitis with polyps.


Eligibility criteria:
inclusion criteria: 1. all meet the diagnostic criteria of crswnp in epos2020 (age 18-70 years old); 2. investigator-assessed endoscopic bilateral nasal polyp size score (npss) was greater than or equal to 4 (minimum score of 2 per nasal cavity); exclusion criteria: 1. oral glucocorticoid contraindications, such as diabetes, femoral head necrosis, gastric ulcer, etc. 2. medication history of oral glucocorticoids or immunomodulator within 1 months before enrollment, antibiotics within 2 weeks; 3. fungal sinusitis, allergic fungal sinusitis (afrs), cystic fibrosis, primary ciliary dyskinesia
predictors for nasal intermittent positive pressure ventilation failure for premature infants with respiratory distress syndrome

Conditions: Respiratory Distress Syndrome, Newborn; Premature

Summary: non-invasive respiratory support methods have been widely used in premature babies with respiratory distress syndrome (rds) which has changed the basic management of premature babies in the early period. according to the 2019 european guidelines on rds management, early nasal cpap is recommended as first-line therapy in infants \<30 weeks of age who are at risk of rds who do not require mechanical ventilation (mv). however, some of the premature babies have faced non-invasive ventilation failure. remarkably, infants who experience non-invasive ventilation failure are at increased risk of death, pneumothorax, intraventricular hemorrhage, and bronchopulmonary dysplasia (bpd), among other morbidities. in non-invasive ventilation failure, although demographic factors such as small gestational age, low birth weight, and male gender play a role, it has been suggested that surfactant deficiency may also play an important role. the most frequently reported risk factor in predicting non-invasive failure in studies is the fraction of inspiring oxygen during the first hours of life. in addition, positive end-expiratory airway pressure (peep) required for patient stabilization was found to be a potential predictor. however, there are still limited data to predict non-invasive ventilation failure. "which newborns are at high risk for non-invasive ventilation failure?" and "when should the surfactant be applied?". the study is a single-center, prospective study to evaluate prognostic factors, and most importantly to define the fio2 threshold, which is an indicator of possible non-invasive ventilation failure in infants supported with nasal intermittent positive pressure ventilation.


Eligibility criteria:
inclusion criteria: * \<32 weeks preterm babies * those who have received nasal intermittent positive pressure ventilation exclusion criteria: * babies born\> 32 weeks * babies with congenital anomalies * babies who have intubated in the delivery room * babies whose parents refuse to participitate
is acute appendicitis still a clinical diagnosis?

Conditions: Appendicitis

Summary: this study aims to investigate the use of preoperative diagnostic imaging before appendectomy in denmark and whether it has changed over time during the period from 2000-15. secondly, the study aims to investigate regional, age and gender differences in the same setting.

acute appendicitis is the most common cause of abdominal pain (1) and appendectomy is the most common emergency surgical procedure performed worldwide (2). during the last decades, there has been a paradigm shift in both diagnosis and treatment of appendicitis - surgical treatment has changed from open to laparoscopic appendectomy (3). acute appendicitis has traditionally been a clinical diagnosis, but the use of preoperative diagnostic imaging has, in some countries, increased dramatically (4). the use of computed tomography (ct) before appendectomy is in the united states up to 90%, in england 13% and in holland almost all patients undergo ultrasound and/or ct before appendectomy (1). the use of antibiotics can be successful in the treatment of uncomplicated appendicitis verified on ct, and the use of ct has significantly lowered the negative appendectomy rate compared to clinical evaluation only (1). but the use of ct is inevitably inducing radiation and increasing lifetime risk of cancer - especially in younger patients who most frequently present with acute appendicitis (1,5). it is estimated that ct of the abdominal region can avoid 12 negative appendectomies but at the cost of one cancer death due to radiation (5). in denmark surgery is still the only treatment for appendicitis, but how is appendicitis diagnosed? is acute appendicitis still a clinical diagnosis?

Eligibility criteria:
inclusion criteria: * patients with a diagnosis for appendicitis undergoing appendectomy during the same admission during the period 2000-15 exclusion criteria: * none

Keywords: appendicitis appendectomy preoperative diagnostic imaging